← Back to Methodology
RQS Scoring Log

Carnosine

Longevity & Cellular Aging· Human RCT· Scored May 2026· View compound profile →
73 /100
Moderate Evidence
7 dimensions · 100 points total · Methodology by PeptideClear
Dimension Breakdown
DimensionScoring NotesScore
Study Design
Multiple human RCTs across cognitive aging, exercise performance, and antioxidant effects. Also studied in clinical populations (diabetes, cardiovascular). Strong design quality — multiple independent RCTs.
25 / 25
Sample Size
Individual trials typically 50-150 participants. Not massive but well-powered for aging/supplement research.
16 / 20
Replication
Replicated across multiple independent groups — Australian (Alan Stegen group), European, and Asian research groups independently confirm performance and neuroprotective effects.
15 / 20
Journal Impact Factor
Published in FASEB Journal (IF ~5), British Journal of Nutrition (IF ~3.5), Journal of the International Society of Sports Nutrition (IF ~4). Solid mid-tier journals.
8 / 15
Funding Independence
Mix of academic and some nutraceutical industry funding. Australian academic groups (University of Melbourne) have published independently. Mixed but leaning independent.
4 / 10
Population Diversity
Studied across older adults, athletes, and diabetic patients. Mix of demographics but not globally diverse.
3 / 5
Researcher h-Index
Alan Stegen (University of Melbourne) and Michael Belber — moderate academic h-Indexes (10-19 range) in sports nutrition and aging.
2 / 5